Anzeige
Mehr »
Login
Sonntag, 25.02.2024 Börsentäglich über 12.000 News von 683 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJJQ | ISIN: FR001400JX97 | Ticker-Symbol: PXH1
Frankfurt
23.02.24
17:41 Uhr
0,300 Euro
-0,050
-14,29 %
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
PIXIUM VISION SA Chart 1 Jahr
5-Tage-Chart
PIXIUM VISION SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,3800,41224.02.
GlobeNewswire (Europe)
518 Leser
Artikel bewerten:
(2)

Pixium Vision: Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Update on the receivership proceedings: submission of a takeover offer to the court-appointed administrators

Paris, France, November 20, 2023 - 5:45 pm (CET) - Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, whose safeguard proceedings (procédure de sauvegarde) were converted into receivership (redressement judiciaire) by decision of the Paris Commercial Court on November 13, 2023, announces that the court-appointed administrators have today received a takeover offer for the assets and activities of Pixium.

The date for the hearing to examine the takeover offer will be set by the Commercial Court by the end of November.

The Company draws investors' attention to the fact that, given the current offer and the Company's level of indebtedness, the sale proceeds received in the context of the Company's insolvency proceedings do not allow a total or partial reimbursement of shareholders.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com (mailto:investors@pixium-vision.com)

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

Attachment

  • Pixium - PR update on the receivership (offer received) - 20.11.2023 (https://ml-eu.globenewswire.com/Resource/Download/ce525a41-acd6-42c3-8ecf-8c86565ca8d5)

China Knaller 2024: Diese 5 Aktien sind echte Geheim-Tipps
Der kostenfreie China-Report enthüllt gleich fünf Geheim-Tipps, die zu echten Outperformern werden könnten. Lesen Sie den kostenfreien Report und nutzen Sie die Chancen rechtzeitig!
Hier klicken
© 2023 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.